Targeting the Resistant Tumor Microenvironment in Lymphoma: From Basic Science to Artificial Intelligence

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 2044

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA
Interests: lymphoma; tumor microenvironment; immunotherapy; artificial intelligence
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lymphomas are heterogeneous groups of neoplasms that originate from the aberrant proliferation of immune cells, including B lymphocytes, T lymphocytes, and natural killer (NK) cells. While tumoral initiation is associated with the accumulation of genetic mutations, the tumor microenvironment (TME) is a crucial infrastructure in lymphomagenesis, as they are strongly dependent on the TME for various steps of malignancies. The TME constitutes a dynamic ecosystem composed of immune and stromal cells, implicated from progression to metastasis. Despite recent advances in lymphoma treatment, achieving a durable response remains poor, leading to relapse and resistance to various immunotherapies. 

Current challenges in reaching a complete response include the high degree of heterogeneity in the TME composition and the multitude mechanisms through which the TME can counteract the efficacy of therapy. The high pressure exerted by treatments results in the modulation of TME response prompting necessary signals for the development of resistant clones against therapeutic regimens. 

Therefore, further research is necessary to explore the complex molecular and cellular ecosystem of lymphoma disease and reveal innovative microenvironmental targets that can reduce the high incidence of relapse and resistance and minimize the development of drug-resistant clones.  

This Special Issue welcomes reviews and innovative research articles spanning from basic science to artificial intelligence approaches on the TME-lymphoma crosstalk. The aim is to enhance our understanding of the influence of TME on malignancies and improve therapy effectiveness.

Dr. Rada Amin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lymphoma
  • tumor microenvironment
  • tumor–immune cell interaction
  • immunotherapy
  • machine learning
  • bioimaging
  • artificial intelligence
  • immunology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1372 KiB  
Review
Applications of Multimodal Artificial Intelligence in Non-Hodgkin Lymphoma B Cells
by Pouria Isavand, Sara Sadat Aghamiri and Rada Amin
Biomedicines 2024, 12(8), 1753; https://doi.org/10.3390/biomedicines12081753 - 5 Aug 2024
Cited by 1 | Viewed by 1486
Abstract
Given advancements in large-scale data and AI, integrating multimodal artificial intelligence into cancer research can enhance our understanding of tumor behavior by simultaneously processing diverse biomedical data types. In this review, we explore the potential of multimodal AI in comprehending B-cell non-Hodgkin lymphomas [...] Read more.
Given advancements in large-scale data and AI, integrating multimodal artificial intelligence into cancer research can enhance our understanding of tumor behavior by simultaneously processing diverse biomedical data types. In this review, we explore the potential of multimodal AI in comprehending B-cell non-Hodgkin lymphomas (B-NHLs). B-cell non-Hodgkin lymphomas (B-NHLs) represent a particular challenge in oncology due to tumor heterogeneity and the intricate ecosystem in which tumors develop. These complexities complicate diagnosis, prognosis, and therapy response, emphasizing the need to use sophisticated approaches to enhance personalized treatment strategies for better patient outcomes. Therefore, multimodal AI can be leveraged to synthesize critical information from available biomedical data such as clinical record, imaging, pathology and omics data, to picture the whole tumor. In this review, we first define various types of modalities, multimodal AI frameworks, and several applications in precision medicine. Then, we provide several examples of its usage in B-NHLs, for analyzing the complexity of the ecosystem, identifying immune biomarkers, optimizing therapy strategy, and its clinical applications. Lastly, we address the limitations and future directions of multimodal AI, highlighting the need to overcome these challenges for better clinical practice and application in healthcare. Full article
Show Figures

Figure 1

Back to TopTop